Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Reseña (Review)

Targeting Viral Transcription for HIV Cure Strategies

  • Izquierdo-Pujol, Jon|||0000-0002-5903-9909
  • Puertas, Maria C.|||0000-0002-6750-2318
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Moron-Lopez, Sara|||0000-0003-0800-9205
Combination antiretroviral therapy (ART) suppresses viral replication to undetectable levels, reduces mortality and morbidity, and improves the quality of life of people living with HIV (PWH). However, ART cannot cure HIV infection because it is unable to eliminate latently infected cells. HIV latency may be regulated by different HIV transcription mechanisms, such as blocks to initiation, elongation, and post-transcriptional processes. Several latency-reversing (LRA) and -promoting agents (LPA) have been investigated in clinical trials aiming to eliminate or reduce the HIV reservoir. However, none of these trials has shown a conclusive impact on the HIV reservoir. Here, we review the cellular and viral factors that regulate HIV-1 transcription, the potential pharmacological targets and genetic and epigenetic editing techniques that have been or might be evaluated to disrupt HIV-1 latency, the role of miRNA in post-transcriptional regulation of HIV-1, and the differences between the mechanisms regulating HIV-1 and HIV-2 expression.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa|||0000-0002-8202-6751
  • Ayllon-Hermida, Alberto|||0000-0002-9566-6934
  • Cortés Serra, Núria|||0000-0001-5396-3757
  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Bech-Serra, Joan-Josep|||0000-0003-3486-781X
  • Aparici-Herraiz, Iris|||0000-0002-6014-8221
  • Nicolau Fernández, Marc|||0000-0001-7211-796X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Gutierrez-Chamorro, Lucia
  • Marfil, Sílvia|||0000-0003-0139-5000
  • Pradenas, Edwards|||0000-0001-5162-8920
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester|||0000-0002-5215-7363
  • Urrea, Víctor|||0000-0002-2577-856X
  • Fraile, Lorenzo|||0000-0002-8980-5862
  • Montoya, Maria|||0000-0002-5703-7360
  • Vergara-Alert, Júlia|||0000-0001-7484-444X
  • Segalés Coma, Joaquim|||0000-0002-1539-7261
  • Carrillo, Jorge|||0000-0003-0221-5948
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Blanco, Julià|||0000-0002-2225-0217
  • Fernandez-Becerra, Carmen|||0000-0001-5154-0013
  • De La Torre, Carolina
  • Pinazo, Maria-Jesus|||0000-0002-4237-1075
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Del Portillo, Hernando A.|||0000-0002-5278-3452
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein's and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

OAS1 and OAS3 genetic variants enhance inflammatory responses to SARS-CoV-2

  • DeDiego, Marta L.|||0000-0002-7888-7372
  • López-Fernández-Sobrino, Raúl
  • Pedragosa, Jordi|||0000-0001-8493-4545
  • López-García, Darío
  • Nogales, Aitor
  • Durbán, Jordi
  • Cardona, Fernando
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Rivero, Vanessa
  • Vazquez-Utrilla, Paula
  • Palomo Sanchez-Grande, Laura
  • Cobo, Miriam
  • Lloret, Lara
  • Márquez-Kisinousky, Leonardo
  • Ruiz-Jaén, Francisca
  • Lozano, Francisco
  • Sibila, Oriol|||0000-0002-4833-6713
  • Faner, Rosa|||0000-0002-8159-0115
  • Castro Rebollo, Pedro|||0000-0002-6118-8970
  • Domingo, Carlos
  • Robles, Verónica
  • Bedini, Josep L.
  • Rico, Verónica
  • Aguero, Daiana
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Martín Nalda, Andrea|||0000-0002-1715-153X
  • Martínez, Alba Parra
  • Colobrán Oriol, Roger|||0000-0002-5964-536X
  • Soler Palacín, Pere|||0000-0002-0346-5570
  • Serra-Llovich, Alexandre|||0000-0001-8318-851X
  • Dietl, Beatriz|||0000-0001-6011-6986
  • Arranz, M. Jesús
  • Dalmau, David|||0000-0003-1936-478X
  • Signes-Costa, Jaime
  • Gil-Carbonell, Joan
  • Todolí, José
  • Martínez, Jacobo
  • Rojo, Silvia
  • Fiz-López, Aida
  • Arribas, Elisa
  • Cal-Sabater, Paloma
  • Bernado, David
  • Vogel, Marina
  • Wiemann, Stefan|||0000-0003-4683-3174
  • Abolhassani, Hassan|||0000-0002-4838-0407
  • Pan-Hammarström, Qiang|||0000-0003-1990-8804
  • Pujol, Aurora|||0000-0002-9606-0600
  • Su, Helen C.|||0000-0002-5582-9110
  • Lee, Danyel|||0000-0003-3124-0245
  • Zhang, Shen-Ying|||0000-0002-9449-3672
  • Casanova, Jean-Laurent|||0000-0002-7782-4169
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Pérez-Tur, Jordi|||0000-0002-9111-1712
  • Planas, Anna Maria|||0000-0002-6147-1880
Recessive deficiency in 2',5'-oligoadenylate synthetase (OAS) or RNase L can cause systemic inflammation in children with SARS-CoV-2 infection, but its role in adult respiratory disease is unclear. We analyzed rare OAS1/OAS3 variants and the common OAS1 rs10774671 polymorphism in 342 COVID-19 patients, assessing enzymatic activity, RNase L activation, viral replication, and inflammation in cell systems and Oas3-deficient mice. Rare heterozygous variants showed impaired RNase L activation but were not enriched in pneumonia cases. In contrast, the rs10774671 A/A genotype (OAS1-p42 isoform) was associated with severe disease (OR = 2.28; 95% CI = 1.13-4.58; p = 0.0107) and reduced viral control despite intact RNase L activation. OAS3 and OAS1-p46 isoform limited viral replication and inflammatory responses, whereas Oas3-deficient mice showed increased cytokines. These findings suggest that common OAS1 variation influences COVID-19 severity, while rare OAS variants may affect inflammation regulation rather than respiratory pathology.
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children

  • Lee, Danyel
  • COVID Human Genetic Effort
  • Zhang, Shen-Ying
Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition that follows benign COVID-19. We report autosomal recessive deficiencies of OAS1, OAS2, or RNASEL in five unrelated children with MIS-C. The cytosolic double-stranded RNA (dsRNA)-sensing OAS1 and OAS2 generate 2'-5'-linked oligoadenylates (2-5A) that activate the single-stranded RNA-degrading ribonuclease L (RNase L). Monocytic cell lines and primary myeloid cells with OAS1, OAS2, or RNase L deficiencies produce excessive amounts of inflammatory cytokines upon dsRNA or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stimulation. Exogenous 2-5A suppresses cytokine production in OAS1-deficient but not RNase L-deficient cells. Cytokine production in RNase L-deficient cells is impaired by MDA5 or RIG-I deficiency and abolished by mitochondrial antiviral-signaling protein (MAVS) deficiency. Recessive OAS-RNase L deficiencies in these patients unleash the production of SARS-CoV-2-triggered, MAVS-mediated inflammatory cytokines by mononuclear phagocytes, thereby underlying MIS-C., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R21AI160576), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High-Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU Program ANR-21-RHUS-08 (COVIFERON), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), and Paris Cité University. We acknowledge support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH under award R01AI104887 to R.H.S. and S.R.W. The Laboratory of Human Evolutionary Genetics (Institut Pasteur) is supported by the Institut Pasteur, the Collège de France, the French Government’s Investissement d’Avenir program, Laboratoires d’Excellence “Integrative Biology of Emerging Infectious Diseases” (ANR-10-LABX-62-IBEID) and “Milieu Intérieur” (ANR-10-LABX-69-01), the Fondation de France (no. 00106080), the FRM (Equipe FRM DEQ20180339214 team), and the ANR COVID-19-POPCELL (ANR-21-CO14-0003-01). A.Puj. is supported by ACCI20-759 CIBERER, EasiGenomics H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021-ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. The Canarian Health System sequencing hub was funded by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación MAPFRE Guanarteme (OA21/131), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The CoV-Contact Cohort was funded by the French Ministry of Health and the European Commission (RECOVER project). Our studies are also funded by the Ministry of Health of the Czech Republic Conceptual Development of Research Organization (FNBr, 65269705) and ANID COVID0999 funding in Chile. G. Novelli and A. Novelli are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark. A.M.P., M.L.D., and J.P.-T. are supported by the Inmungen-CoV2 project of CSIC. This work was supported in part by the Intramural Research Program of the NIAID, NIH. The research work of A.M..P, M.L.D., and J.P.-T. was funded by the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). I.M. is a senior clinical investigator at FWO Vlaanderen supported by a VIB GC PID grant, by FWO grants G0B5120N (DADA2) and G0E8420N, and by the Jeffrey Modell Foundation. I.M. holds an ERC-StG MORE2ADA2 grant and is also supported by ERN-RITA.​ A.Y. is supported by fellowships from the European Academy of Dermatology and Venereology and the Swiss National Science Foundation and by an Early Career Award from the Thrasher Research Fund. Y.-H.C. is supported by an A*STAR International Fellowship (AIF). M.O. was supported by the David Rockefeller Graduate Program, the New York Hideyo Noguchi Memorial Society (HNMS), the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the National Cancer Institute (NCI) F99 Award (F99CA274708). A.A.A. was supported by Ministerio de Ciencia Tecnología e Innovación MINCIENCIAS, Colombia (111584467551/CT 415-2020). D.L. is supported by a fellowship from the FRM for medical residents and fellows. E.H. received funding from the Bank of Montreal Chair of Pediatric Immunology, Foundation of CHU Sainte-Justine, CIHR grants PCC-466901 and MM1-181123, and a Canadian Pediatric Society IMPACT study. Q.P.-H. received funding from the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650), the Swedish Research Council, and the Knut and Alice Wallenberg Foundation. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, and R01AI161444; a George Mason University Fast Grant; the G. Harold and Leila Y. Mathers Charitable Foundation; the Meyer Foundation; and the Bawd Foundation. R.P.L. is on the board of directors of both Roche and the Roche subsidiary Genentech. J.L.P. was supported by a Francois Wallace Monahan Postdoctoral Fellowship at the Rockefeller University and by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018).
Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

  • Marchal, Astrid
  • COVID Clinicians
  • Bolze, Alexandre
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer's Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (Equation 201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of business in EMEA, and the General Atlantic Foundation, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. A.N.S. is supported by European Union’s Horizon Health research and innovation program under grant agreement No. 101057100, project UNDINE. S.G.T. is supported by an Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a University of New South Wales Sydney COVID Rapid Response Initiative grant. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 10101616. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health and Fondation AP-HP Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0048). Y.Z. is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. This project has received funding from the Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959), the Swiss National Science Foundation (grant # 310030L_197721 to J.F.), and ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grants AJF202019 and AJF20259 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I. Erkizia, E. Grau, M. Massanella, and J. Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling, and processing.
IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon-Hermida, Alberto
  • Cortes-Serra, Núria
  • Resa-Infante, Patricia
  • Bech-Serra, Joan Josep
  • Aparici-Herraiz, Iris
  • Nicolau-Fernandez, Marc
  • Erkizia, Itziar
  • Gutierrez-Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester
  • Urrea, Victor
  • Fraile, Lorenzo
  • Montoya, Maria
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Fernandez-Becerra, Carmen
  • de La Torre, Carolina
  • Pinazo, Maria-Jesus
  • Martinez-Picado, Javier
  • del Portillo, Hernando A.
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein’s and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies., info:eu-repo/semantics/publishedVersion
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Higher COVID-19 pneumonia risk associated with anti-IFN-α than with anti-IFN-ω auto-Abs in children

  • Bastard, Paul
  • Gervais, Adrian
  • Taniguchi, Maki
  • Saare, Liisa
  • Särekannu, Karita
  • Voyer, Tom Le
  • Philippot, Quentin
  • Rosain, Jérémie
  • Bizien, Lucy
  • Asano, Takaki
  • Garcia-Prat, Marina
  • Parra-Martínez, Alba
  • Migaud, Mélanie
  • Tsumura, Miyuki
  • Conti, Francesca
  • Belot, Alexandre
  • Rivière, Jacques G.
  • Morio, Tomohiro
  • Tanaka, Junko
  • Javouhey, Etienne
  • Haerynck, Filomeen
  • Duvlis, Sotirija
  • Ozcelik, Tayfun
  • Keles, Sevgi
  • Tandjaoui-Lambiotte, Yacine
  • Escoda, Simon
  • Husain, Maya
  • Pan-Hammarström, Qiang
  • Pérez-Tur, Jordi
  • Planas, Anna M.
  • Hammarström, Lennart
  • Ahlijah, Gloria
  • Haidar, Anthony Abi
  • Soudee, Camille
  • Arseguel, Vincent
  • Abolhassani, Hassan
  • Sahanic, Sabina
  • Tancevski, Ivan
  • Nukui, Yoko
  • Hayakawa, Seiichi
  • Chrousos, George P.
  • Michos, Athanasios
  • Tatsi, Elizabeth Barbara
  • Filippatos, Filippos
  • Rodriguez-Palmero, Agusti
  • Troya, Jesus
  • Tipu, Imran
  • Meyts, Isabelle
  • Roussel, Lucie
  • Ostrowski, Sisse Rye
  • Schidlowski, Laire
  • Prando, Carolina
  • Condino-Neto, Antonio
  • Cheikh, Nathalie
  • Bousfiha, Ahmed A.
  • Bakkouri, Jalila El
  • Peterson, Pärt
  • Pujol, Aurora
  • Lévy, Romain
  • Quartier, Pierre
  • Vinh, Donald C.
  • Boisson, Bertrand
  • Béziat, Vivien
  • Zhang, Shen Ying
  • Borghesi, Alessandro
  • Pession, Andrea
  • Andreakos, Evangelos
  • Marr, Nico
  • Mentis, Alexios Fotios A.
  • Mogensen, Trine H.
  • Rodríguez-Gallego, Carlos
  • Soler-Palacin, Pere
  • Colobran, Roger
  • Tillmann, Vallo
  • Neven, Bénédicte
  • Trouillet-Assant, Sophie
  • Brodin, Petter
  • Abel, Laurent
  • Jouanguy, Emmanuelle
  • Zhang, Qian
  • Martinón-Torres, Federico
  • Salas, Antonio
  • Gómez-Carballa, Alberto
  • Gonzalez-Granado, Luis I.
  • Kisand, Kai
  • Okada, Satoshi
  • Puel, Anne
  • Cobat, Aurélie
  • Casanova, Jean-Laurent
  • Aguilera-Albesa, Sergio
  • Alkhater, Suzan A.
  • Alkan, Gulsum
  • Castagnoli, Riccardo
  • Cyrus, Cyril
  • Bozdemir, Sefika Elmas
  • Emiroglu, Melike
  • Gulhan, Belgin
  • Erdeniz, Emine Hafize
  • Hatipoglu, Nevin
  • Bayhan, Gülsün Iclal
  • Jabandziev, Petr
  • Yuksek, Saliha Kanik
  • COVID Human Genetic Effort
We found that 19 (10.4%) of 183 unvaccinated children hospitalized for COVID-19 pneumonia had autoantibodies (auto-Abs) neutralizing type I IFNs (IFN-α2 in 10 patients: IFN-α2 only in three, IFN-α2 plus IFN-ω in five, and IFN-α2, IFN-ω plus IFN-β in two; IFN-ω only in nine patients). Seven children (3.8%) had Abs neutralizing at least 10 ng/ml of one IFN, whereas the other 12 (6.6%) had Abs neutralizing only 100 pg/ml. The auto-Abs neutralized both unglycosylated and glycosylated IFNs. We also detected auto-Abs neutralizing 100 pg/ml IFN-α2 in 4 of 2,267 uninfected children (0.2%) and auto-Abs neutralizing IFN-ω in 45 children (2%). The odds ratios (ORs) for life-threatening COVID-19 pneumonia were, therefore, higher for auto-Abs neutralizing IFN-α2 only (OR [95% CI] = 67.6 [5.7–9,196.6]) than for auto-Abs neutralizing IFN-ω only (OR [95% CI] = 2.6 [1.2–5.3]). ORs were also higher for auto-Abs neutralizing high concentrations (OR [95% CI] = 12.9 [4.6–35.9]) than for those neutralizing low concentrations (OR [95% CI] = 5.5 [3.1–9.6]) of IFN-ω and/or IFN-α2., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364, R01AI163029, and R21AI160576), the National Center for Advancing Translational Sciences, the NIH Clinical and Translational Science Award program (UL1TR001866), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JPB Foundation, the Stavros Niarchos Foundation Institute for Global Infectious Disease Research, the program “Investissement d’Avenir” launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANRSCOV05, ANR GENVIR (ANR-20-CE93-003), ANR AI2D (ANR-22- CE15-0046), and ANR AAILC (ANR-21-LIBA-0002) projects, the European Union’s Horizon 2020 research and innovation program under grant agreement no. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU COVIFERON Program (ANR-21-RHUS-08), the Square Foundation, Grandir - Fonds de solidarite pour l ´ ’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Sante et de la Recherche M ´ edicale (IN- ´ SERM), REACTing-INSERM, the University of Paris Cite and ´ Imagine Institute, Battersea & Bowery Advisory Group, and William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of Business in EMEA, and the General Atlantic Foundation. I. Meyts is a senior clinical researcher at FWO Vlaanderen; I. Meyts is funded by the European Research Council under HORIZON-HLTL-2021-ID: 101057100 "Undine," KU Leuven C16/18/007, and FWO grant G0B5120N (DADA2). L.D. Notarangelo and H.C. Su (members of the COVID Human Genetic Effort) were supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. P. Bastard was supported by the French Foundation for Medical Research (FRM, EA20170638020). P. Bastard and T. Le Voyer were supported by the MD-PhD program of the Imagine Institute (with the support of the Fondation Bettencourt-Schueller). P. Bastard was supported by the “Poste CCA-INSERM-Bettencourt” (with the support of the Fondation Bettencourt-Schueller). S. Okada was supported by MEXT/JSPS KAKENHI (grant numbers 22H03041 and 22KK0113) and AMED (grant numbers JP21fk0108436 and JP22fk0108514). L.I. Gonzalez-Granado is supported by the Instituto de Salud Carlos III (ISCIII) through the project FIS-PI21/01642 and cofunded by the European Union. D.C. Vinh is supported by a Fonds de Recherche du Quebec - Sant ´ e, Senior Clinician-Scientist scholar award. ´ Q. Pan-Hammarstrom was funded by the Swedish Research ¨ Council, and the Knut and Alice Wallenberg Foundation. K. Kisand’s laboratory was funded by the Estonian Research Council grants PRG1117 and PRG1428. This study also received support from ISCIII (TRINEO: PI22/00162; DIAVIR: DTS19/00049; ResviOmics: PI19/01039 [A. Salas]; ReSVinext: PI16/01569 [F. Martinón-Torres]; Enterogen: PI19/01090 [F. Martinón-Torres]); OMI-COVI-VAC (PI22/00406 [F. Martinón-Torres] jointly financed by FEDER), GAIN: Grupos con Potencial de Crecimiento (IN607B 2020/08 [A. Salas]); ACIS: BI-BACVIR (PRIS-3 [A. Salas]), and CovidPhy (SA 304 C [A. Salas]); and consorcio Centro de Investigación Biomedica en Red de Enfermedades Respira- ´ torias (CB21/06/00103; F. Martinón-Torres); GEN-COVID (IN845D 2020/23, F. Martinón-Torres) and Grupos de Referencia Competitiva (IIN607A2021/05, F. Martinón-Torres). The study was funded by ISCIII (COV20_01333, COV20_01334, PI16/ 00759, PI18/00223, PI19/00208, PI20/00876, and PI21/00211), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/ FEDER, EU), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43, PIFIISC22/27), Grupo DISA (OA18/017), Fundación MAPFRE Guanarteme (OA21/131), Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas cient´ıficas del ITER para colaborar en la lucha contra la COVID-19”). A. Pujol is supported by ACCI20-759 CIBERER, H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021- ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. This research is supported by the European Reference Network for Rare Immunodeficiency, Autoinflammatory and Autoimmune Diseases. Open Access funding provided by Rockefeller University., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Humans with inherited MyD88 and IRAK-4 deficiencies are predisposed to hypoxemic COVID-19 pneumonia

  • García-García, Ana
  • Pérez de Diego, Rebeca
  • Flores, Carlos
  • Rinchai, Darawan
  • Solé-Violán, Jordi
  • Deyà-Martínez, Àngela
  • García-Solis, Blanca
  • Lorenzo-Salazar, José M.
  • Hernández-Brito, Elisa
  • Lanz, Anna-Lisa
  • Moens, Leen
  • Bucciol, Giorgia
  • Almuqamam, Mohamed
  • Domachowske, Joseph B.
  • Colino, Elena
  • Santos-Perez, Juan Luis
  • Marco, Francisco M.
  • Pignata, Claudio
  • Bousfiha, Aziz
  • Turvey, Stuart E.
  • Bauer, Stefanie
  • Haerynck, Filomeen
  • Ocejo-Vinyals, Javier Gonzalo
  • Lendinez, Francisco
  • Prader, Seraina
  • Naumann-Bartsch, Nora
  • Pachlopnik Schmid, Jana
  • Biggs, Catherine M.
  • Hildebrand, Kyla
  • Dreesman, Alexandra
  • Cárdenes, Miguel Ángel
  • Ailal, Fatima
  • Benhsaien, Ibtihal
  • Giardino, Giuliana
  • Molina-Fuentes, Agueda
  • Fortuny, Claudia
  • Madhavarapu, Swetha
  • Conway, Daniel H.
  • Prando, Carolina
  • Schidlowski, Laire
  • Martínez de Saavedra Álvarez, María Teresa
  • Alfaro, Rafael
  • Rodríguez de Castro, Felipe
  • Meyts, Isabelle
  • Hauck, Fabian
  • Puel, Anne
  • Bastard, Paul
  • Boisson, Bertrand
  • Jouanguy, Emmanuelle
  • Abel, Laurent
  • Cobat, Aurélie
  • Zhang, Qian
  • Casanova, Jean-Laurent
  • Alsina, Laia
  • Rodríguez-Gallego, Carlos
X-linked recessive deficiency of TLR7, a MyD88- and IRAK-4-dependent endosomal ssRNA sensor, impairs SARS-CoV-2 recognition and type I IFN production in plasmacytoid dendritic cells (pDCs), thereby underlying hypoxemic COVID-19 pneumonia with high penetrance. We report 22 unvaccinated patients with autosomal recessive MyD88 or IRAK-4 deficiency infected with SARS-CoV-2 (mean age: 10.9 yr; 2 mo to 24 yr), originating from 17 kindreds from eight countries on three continents. 16 patients were hospitalized: six with moderate, four with severe, and six with critical pneumonia, one of whom died. The risk of hypoxemic pneumonia increased with age. The risk of invasive mechanical ventilation was also much greater than in age-matched controls from the general population (OR: 74.7, 95% CI: 26.8-207.8, P < 0.001). The patients' susceptibility to SARS-CoV-2 can be attributed to impaired TLR7-dependent type I IFN production by pDCs, which do not sense SARS-CoV-2 correctly. Patients with inherited MyD88 or IRAK-4 deficiency were long thought to be selectively vulnerable to pyogenic bacteria, but also have a high risk of hypoxemic COVID-19 pneumonia., The study was funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, PI16/00759, PI18/00223, PI19/ 00208, PI20/00876, and PI21/00211), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER), the Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC19/43 and FIISC22/27), Grupo DISA (OA18/017 and OA22/035), Fundación MAPFRE Guanarteme (OA21/131), Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas cient´ıficas del ITER para colaborar en la lucha contra la COVID- 19”), a 2022 Convocat`oria de Beques de Recerca IRSJD—Carmen de Torres 2022 (2022AR-IRSJD-CdTorres), CERCA Programme/ Generalitat de Catalunya, the Else Kr¨oner-Fresenius Stiftung (EKFS, 2017_A110), the German Federal Ministry of Education and Research (01GM1910C), the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, and the Horizon Europe Framework Programme of the European Union under Grant Agreement no. 101057100. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Research Council Executive Agency. Neither the European Union nor the granting authority can be held responsible for them., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A common form of dominant human IFNAR1 deficiency impairs IFN-α and -ω but not IFN-β-dependent immunity

  • Al Qureshah, Fahd
  • COVID-19 HGE Consortium members
  • Pérez-Tur, Jordi
  • Casanova, Jean-Laurent
34 páginas, 7 figuras, 1 tabla. Anexada lista completa de autores del COVID-19 HGE Consortium members, Autosomal recessive deficiency of the IFNAR1 or IFNAR2 chain of the human type I IFN receptor abolishes cellular responses to IFN-α, -β, and -ω, underlies severe viral diseases, and is globally very rare, except for IFNAR1 and IFNAR2 deficiency in Western Polynesia and the Arctic, respectively. We report 11 human IFNAR1 alleles, the products of which impair but do not abolish responses to IFN-α and -ω without affecting responses to IFN-β. Ten of these alleles are rare in all populations studied, but the remaining allele (P335del) is common in Southern China (minor allele frequency ≈2%). Cells heterozygous for these variants display a dominant phenotype in vitro with impaired responses to IFN-α and -ω, but not -β, and viral susceptibility. Negative dominance, rather than haploinsufficiency, accounts for this dominance. Patients heterozygous for these variants are prone to viral diseases, attesting to both the dominance of these variants clinically and the importance of IFN-α and -ω for protective immunity against some viruses., This study was supported in part by the St. Giles Foundation; the Rockefeller University; the Howard Hughes Medical Institute; Institut National de la Sant´ e et de la Recherche M´ edicale (INSERM); the Imagine Institute; Paris Cit´ e University; the Fisher Center for Alzheimer’s Research Foundation; the Meyer Foundation; the JPB Foundation; the National Center for Research Resources; the National Center for Advancing Sciences of the National Institutes of Health (NIH) (UL1TR001866); NIH (R01AI163029); American Lung Association (COVID-1026207); Stavros Niarchos Foundation (SNF) as part of its grant to the SNF Institute for Global Infectious Disease Research at The Rockefeller University; the Square Foundation; Grandir- Fonds de solidarit´ epour l’enfance; theFondation du Souffle; the SCOR Corporate Foundation for Science; the Battersea and Bowery Advisory Group; the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10IAHU-01); the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID); ANR GENVIR(ANR-20-CE93-003);ANRAAILC(ANR-21-LIBA-0002); ANR AI2D (ANR-22-CE15-0046); ANR GENFLU (ANR-22-CE920004); the ANR-RHUCOVIFERONprogram(ANR-21-RHUS-08); the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE); the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics); W.E. Ford, General Atlantic’s Chairman and Chief Executive Officer, G. Caillaux, General Atlantic’s Co-President, Managing Director and Head of Business in EMEA, and the General Atlantic Foundation; the French Ministry of Higher Education, Research, and Innovation (MESRICOVID-19); REACTing-INSERM. SEAe Consortium was supported by ANR SEA host factors (ANR-18-CE15-0020-01), Institut Pasteur, Institut Pasteur International Network, Fondation M´ erieux, Aviesan Sud, INSERM, Wellcome Trust, Institut de Recherche pour le D´ eveloppement (IRD), and Fondation Total. F. Al Qureshah was funded by the Ibn Rushd Postdoctoral Fellowship by King Abdullah University of Science and Technology (KAUST), and by the King Abdulaziz City for Science and Technology (KACST). P. Bastard was supported by the FRM (EA20170638020), the MD-PhD program of the Imagine Institute (with support from the Fondation Bettencourt-Schueller), and a “Poste CCA-INSERMBettencourt” (with support from the Fondation BettencourtSchueller). Y.L. Lau was supported by the Hong Kong Society for the Relief of Disabled Children for his research on inborn errors of immunity. R. Halwani was supported by the Deanship of Scientific Research, King Saud University, and funded through the Vice Deanship of Scientific Research Chairs; Research Chair of Prince Abdullah Ben Khalid Celiac Disease; Riyadh, Kingdom of Saudi Arabia. F. Vianna was supported in part by the Coordenação de Aperfeiçoamento de Pessoal de N´ ıvel Superior- Brasil (CAPES)- Finance Code 001 and by the Conselho Nacional de Desenvolvimento Cient´ ıfico e Tecnológico (12960/2021-2). Open Access funding provided by Rockefeller University.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

NRF2 controls a diverse network of antiviral effectors with p62 acting as a central restriction factor effective across virus families

  • Pedersen, A.
  • Blay-Cadanet, J.
  • Storgaard, J.
  • Hernáez, Bruno
  • Thyrsted, Jacob
  • Bach-Nielsen, C. S.
  • Twayana, K.
  • Jørgensen, Sofie E.
  • Rio-Bergé, C.
  • Poulsen, C.
  • Thielke, Anne L.
  • Thomsen, E.A.
  • Kalucka, J.
  • Olagnier, David
  • Luo, Yonglun
  • Reggiori, F.
  • Mogensen, Trine
  • Alcamí, Antonio
  • Hansen, Anne Louise
  • Holm, Christian
The transcription factor erythroid 2 (NFE2)-related factor 2 (NRF2) is a key regulator of cellular homeostasis. Recent discoveries have identified agonists of NRF2 as inducers of broad cellular resistance to viral infection including SARS-CoV-2. Nevertheless, it is still unclear to what extent NRF2 itself is an inducer of anti-viral immunity and its downstream antiviral effectors have not been mapped. Here, we first demonstrate through specific genetic activation and silencing that NRF2 restricts SARS-CoV-2 replication. We then used a focused CRISPR-activation screen to map antiviral NRF2-inducible effector genes that restrict replication of SARS-CoV-2, Influenza A virus (IAV), Herpes Simplex virus 1 (HSV1) and Vaccinia virus (VACV). This approach allowed us to identify a range of antiviral effectors each of which restrict members of one or more virus families. Importantly, we identified the NRF2-inducible selective autophagy receptor p62/SQSTM1 as a broadly effective restriction factor across all the tested viruses. Importantly, p62 inhibited SARS-CoV-2 replication in cells treated with the lysosomal inhibitor bafilomycin A1, as well as in cells deficient in the autophagy protein ATG5. Similarly, p62 inhibited replication of HSV1 and IAV independently of ATG5 and ATG16L1 respectively. Thus, NRF2 restricts viral replication through a hitherto underappreciated network of antiviral restriction factors effective across multiple virus families. Importantly, we identify p62 as a broadly acting antiviral effector that restricts viral replication independently of canonical autophagy., This work was supported by Novo Nordisk Foundation through a Hallas-Møller Ascending Investigator Grant (NNF21OC0066798) and a Novo Nordisk project grant in Bioscience and Basic Biomedicine (NNF20OC0064589), by the Hørslev Foundation, by the Beckett Foundation, and by Independent Research Fund Denmark (9030-00078B). Work in the laboratory of A.A. was funded by the Spanish Ministry of Science and Innovation and European Union (European Regional Development's Funds, FEDER) grant PID2021-128580OB-I00. THM was supported by NNF Clinical Distinguished Investigator grant (NNF21OC0067157) and EU Horizon Europe; HORIZON-HLTH-2021-DISEASE-04 (101057100-UNDINE). F.R. is supported by Novo Nordisk Foundation (0066384) and Lundbeck Foundation (R383-2022-180) grants., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Defective RNA Polymerase III sensing of mitochondrial DNA in pulmonary epithelial cells impairs type I IFN immunity to SARS-CoV-2

  • Møhlenberg, Michelle
  • Jørgensen, Sofie Eg
  • van der Sluis, Renée Marije
  • Zillinger, Thomas
  • Hinke, Daniëla Maria
  • Hollensen, Anne Kruse
  • Hansen, Anne Louise
  • Hausfater, Pierre
  • Gorochov, Guy
  • Tubach, Florence
  • Ghosn, Jade
  • Laouenan, Cedric
  • Storgaard, Merete
  • Holm, Christian Kanstrup
  • Su, Helen
  • Pérez de Diego, Rebeca
  • Pujol, Aurora
  • Zhang, Shen-Ying
  • Zhang, Qian
  • Sales Luiz Vianna, Fernanda
  • Abel, Laurent
  • Cobat, Aurélie
  • Casanova, Jean-Laurent
  • Mogensen, Trine H.
  • COVID Human genetic Effort
  • Danish COVID-19 clinicians
  • COVID-19 DNABR Group
  • French COVID Cohort Study Group
  • COVIDeF Study Group
  • CoV-Contact Cohort
  • COVID-STORM Clinicians
  • Amsterdam UMC COVID-19 Biobank
  • NIAID-USUHS COVID Study Group
The clinical spectrum of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection ranges from asymptomatic cases to critical COVID-19 pneumonia. To investigate the role of host genetics in susceptibility to critical COVID-19 and identify pathophysiological mechanisms and pathways, we analyzed whole-exome and whole-genome sequencing data from the COVID Human Genetic Effort. We identified 10 rare, monoallelic predicted loss-of-function variants in 18 patients in POLR3A and POLR3C encoding two subunits of RNA polymerase III (POL III), a nuclear multisubunit enzyme, which has been implicated in cytosolic DNA sensing. These variants were deleterious for expression of full-length POLR3A and POLR3C proteins. We demonstrate that human pulmonary A549-hACE2 cells with reduced POLR3A or POLR3C expression exhibit impaired type I IFN responses to transfected mitochondrial DNA (mtDNA) or SARS-CoV-2 infection, together with increased viral replication. Mechanistically, we show that SARS-CoV-2 induces cellular mtDNA release via oligomerization of the mitochondrial voltage-dependent anion channel under virus-induced oxidative stress, enabling POL III-mtDNA interaction. These findings establish POL III as a sensor of endogenous mtDNA released during viral infection and indicate that autosomal dominant POL III haploinsufficiency may predispose individuals to critical COVID-19., T.H.M. has received funding from The Independent Research Council (0134-00006B), the NOVO Nordisk Foundation (NNF21OC0067157 and NNF20OC0064890), The Danish National Research Foundation (DNRF164, CiViA), and Horizon Europe 2021, HORIZON-HLTH-2021-DISEASE-04-07 (UNDINE 101057100). M.M. and R.M.v.d.S. have received funding from Horizon Europe 2021, HORIZON-HLTH-2021-DISEASE-04-07 (UNDINE 101057100) and Læge Sofus Carl Emil Friis og hustru Olga Doris Friis Legat. M.M. received funding from Frimodt-Heineke Fonden and RvdS from A.P. Møller Fonden, Helga og Peter Kornings Fond, and P.A. Messerschmidt og Hustrus Fond., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Proteomics of circulating extracellular vesicles reveals diverse clinical presentations of COVID-19 but fails to identify viral peptides

  • Gualdrón-López, Melisa
  • Ayllon-Hermida, Alberto
  • Cortes-Serra, Núria
  • Resa-Infante, Patricia
  • Bech-Serra, Joan Josep
  • Aparici-Herraiz, Iris
  • Nicolau-Fernandez, Marc
  • Erkizia, Itziar
  • Gutierrez-Chamorro, Lucia
  • Marfil, Silvia
  • Pradenas, Edwards
  • Ávila Nieto, Carlos
  • Cucurull, Bernat
  • Montaner-Tarbés, Sergio
  • Muelas, Magdalena
  • Sotil, Ruth
  • Ballana, Ester
  • Urrea, Victor
  • Fraile, Lorenzo
  • Montoya, Maria
  • Vergara-Alert, Júlia
  • Segalés, Joaquim
  • Carrillo, Jorge
  • Izquierdo-Useros, Nuria
  • Blanco, Julià
  • Fernandez-Becerra, Carmen
  • de La Torre, Carolina
  • Pinazo, Maria-Jesus
  • Martinez-Picado, Javier
  • del Portillo, Hernando A.
Extracellular vesicles (EVs) released by virus-infected cells have the potential to encapsulate viral peptides, a characteristic that could facilitate vaccine development. Furthermore, plasma-derived EVs may elucidate pathological changes occurring in distal tissues during viral infections. We hypothesized that molecular characterization of EVs isolated from COVID-19 patients would reveal peptides suitable for vaccine development. Blood samples were collected from three cohorts: severe COVID-19 patients (G1), mild/asymptomatic cases (G2), and SARS-CoV-2-negative healthcare workers (G3). Samples were obtained at two time points: during the initial phase of the pandemic in early 2020 (m0) and eight months later (m8). Clinical data analysis revealed elevated inflammatory markers in G1. Notably, non-vaccinated individuals in G1 exhibited increased levels of neutralizing antibodies at m8, suggesting prolonged exposure to viral antigens. Proteomic profiling of EVs was performed using three distinct methods: immunocapture (targeting CD9), ganglioside-capture (utilizing Siglec-1) and size-exclusion chromatography (SEC). Contrary to our hypothesis, this analysis failed to identify viral peptides. These findings were subsequently validated through Western blot analysis targeting the RBD of the SARS-CoV-2 Spike protein’s and comparative studies using samples from experimentally infected Syrian hamsters. Furthermore, analysis of the EV cargo revealed a diverse molecular profile, including components involved in the regulation of viral replication, systemic inflammation, antigen presentation, and stress responses. These findings underscore the potential significance of EVs in the pathogenesis and progression of COVID-19., The author(s) declare financial support was received for the research, authorship, and/or publication of this article. The proteomics of EVs isolated by CD9 was performed at the proteomics facility of Utrecht (Netherlands) as part of an EPIC-XS grant (0000205) to CT and HP. The proteomics analyses of EVs isolated by SEC were performed in the IJC Proteomic unit, which is part of the of Proteored, PRB3 and is supported by grant PT17/0019, of the PE I+D+i 2013-2016, funded by ISCIII and ERDF”. The CRG/UPF Proteomics Unit is part of the Spanish Infrastructure for Omics Technologies (ICTS OmicsTech), and it is supported by “Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement de la Generalitat de Catalunya” (2017SGR595). We thank Foundation Dormeur for financial support for the acquisition of the QuantStudio-5 real time PCR system. JM-P was supported by the Spanish Ministry of Science,Innovation and Universities (grants PID2022-139271OB-I00 and CB21/13/00063, Spain), and Fundació La Marató de TV3 (grant 202120-30-31-32, Spain). Funded in part by the European Union. The PCR-4-ALL and UNDINE projects have received funding under the Horizon Europe research and innovation programme (grant agreement No 101095606 and No 101057100 respectively). CF-B and HP acknowledge support from the Spanish Ministry of Science and Innovation (MICINN) (PID2022- 142908OB-I00) and support from the grant CEX2023-0001290-S funded by MCIN/AEI/10.13039/501100011033, and support from the Generalitat de Catalunya through the CERCA Program. This research is part of the ISGlobal’s Program on the Molecular Mechanisms of Malaria which is partially supported by the Fundación Ramón Areces. We also acknowledged the internal funding from IrsiCaixa through the crowdfunding initiative YoMeCorono (JM-P) and ISGlobal (HP) to initiate these studies., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Inborn errors of OAS-RNase L in SARS-CoV-2-related multisystem inflammatory syndrome in children

  • Lee, Danyel
  • COVID Human Genetic Effort
  • Zhang, Shen-Ying
Multisystem inflammatory syndrome in children (MIS-C) is a rare and severe condition that follows benign COVID-19. We report autosomal recessive deficiencies of OAS1, OAS2, or RNASEL in five unrelated children with MIS-C. The cytosolic double-stranded RNA (dsRNA)-sensing OAS1 and OAS2 generate 2'-5'-linked oligoadenylates (2-5A) that activate the single-stranded RNA-degrading ribonuclease L (RNase L). Monocytic cell lines and primary myeloid cells with OAS1, OAS2, or RNase L deficiencies produce excessive amounts of inflammatory cytokines upon dsRNA or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) stimulation. Exogenous 2-5A suppresses cytokine production in OAS1-deficient but not RNase L-deficient cells. Cytokine production in RNase L-deficient cells is impaired by MDA5 or RIG-I deficiency and abolished by mitochondrial antiviral-signaling protein (MAVS) deficiency. Recessive OAS-RNase L deficiencies in these patients unleash the production of SARS-CoV-2-triggered, MAVS-mediated inflammatory cytokines by mononuclear phagocytes, thereby underlying MIS-C., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI088364 and R21AI160576), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High-Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer’s Research Foundation, the Meyer Foundation, the JBP Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (EQU201903007798), the ANR GenMISC (ANR-21-COVR-039), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003) and ANR AABIFNCOV (ANR-20-CO11-0001) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 01057100 (UNDINE), the ANR-RHU Program ANR-21-RHUS-08 (COVIFERON), the Square Foundation, Grandir – Fonds de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, the French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), and Paris Cité University. We acknowledge support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH under award R01AI104887 to R.H.S. and S.R.W. The Laboratory of Human Evolutionary Genetics (Institut Pasteur) is supported by the Institut Pasteur, the Collège de France, the French Government’s Investissement d’Avenir program, Laboratoires d’Excellence “Integrative Biology of Emerging Infectious Diseases” (ANR-10-LABX-62-IBEID) and “Milieu Intérieur” (ANR-10-LABX-69-01), the Fondation de France (no. 00106080), the FRM (Equipe FRM DEQ20180339214 team), and the ANR COVID-19-POPCELL (ANR-21-CO14-0003-01). A.Puj. is supported by ACCI20-759 CIBERER, EasiGenomics H2020 Marató TV3 COVID 2021-31-33, the HORIZON-HLTH-2021-ID: 101057100 (UNDINE), the Horizon 2020 program under grant no. 824110 (EasiGenomics grant no. COVID-19/PID12342), and the CERCA Program/Generalitat de Catalunya. The Canarian Health System sequencing hub was funded by the Instituto de Salud Carlos III (COV20_01333 and COV20_01334), the Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), Fundación MAPFRE Guanarteme (OA21/131), and Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). The CoV-Contact Cohort was funded by the French Ministry of Health and the European Commission (RECOVER project). Our studies are also funded by the Ministry of Health of the Czech Republic Conceptual Development of Research Organization (FNBr, 65269705) and ANID COVID0999 funding in Chile. G. Novelli and A. Novelli are supported by Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark. A.M.P., M.L.D., and J.P.-T. are supported by the Inmungen-CoV2 project of CSIC. This work was supported in part by the Intramural Research Program of the NIAID, NIH. The research work of A.M..P, M.L.D., and J.P.-T. was funded by the European Commission –NextGenerationEU (Regulation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). I.M. is a senior clinical investigator at FWO Vlaanderen supported by a VIB GC PID grant, by FWO grants G0B5120N (DADA2) and G0E8420N, and by the Jeffrey Modell Foundation. I.M. holds an ERC-StG MORE2ADA2 grant and is also supported by ERN-RITA.​ A.Y. is supported by fellowships from the European Academy of Dermatology and Venereology and the Swiss National Science Foundation and by an Early Career Award from the Thrasher Research Fund. Y.-H.C. is supported by an A*STAR International Fellowship (AIF). M.O. was supported by the David Rockefeller Graduate Program, the New York Hideyo Noguchi Memorial Society (HNMS), the Funai Foundation for Information Technology (FFIT), the Honjo International Scholarship Foundation (HISF), and the National Cancer Institute (NCI) F99 Award (F99CA274708). A.A.A. was supported by Ministerio de Ciencia Tecnología e Innovación MINCIENCIAS, Colombia (111584467551/CT 415-2020). D.L. is supported by a fellowship from the FRM for medical residents and fellows. E.H. received funding from the Bank of Montreal Chair of Pediatric Immunology, Foundation of CHU Sainte-Justine, CIHR grants PCC-466901 and MM1-181123, and a Canadian Pediatric Society IMPACT study. Q.P.-H. received funding from the European Union’s Horizon 2020 research and innovation program (ATAC, 101003650), the Swedish Research Council, and the Knut and Alice Wallenberg Foundation. Work in the Laboratory of Virology and Infectious Disease was supported by NIH grants P01AI138398-S1, 2U19AI111825, R01AI091707-10S1, and R01AI161444; a George Mason University Fast Grant; the G. Harold and Leila Y. Mathers Charitable Foundation; the Meyer Foundation; and the Bawd Foundation. R.P.L. is on the board of directors of both Roche and the Roche subsidiary Genentech. J.L.P. was supported by a Francois Wallace Monahan Postdoctoral Fellowship at the Rockefeller University and by a European Molecular Biology Organization Long-Term Fellowship (ALTF 380-2018).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

  • Marchal, Astrid
  • COVID Clinicians
  • Bolze, Alexandre
Human genetic studies of critical COVID-19 pneumonia have revealed the essential role of type I interferon-dependent innate immunity to SARS-CoV-2 infection. Conversely, an association between the HLA-B∗15:01 allele and asymptomatic SARS-CoV-2 infection in unvaccinated individuals was recently reported, suggesting a contribution of pre-existing T cell-dependent adaptive immunity. We report a lack of association of classical HLA alleles, including HLA-B∗15:01, with pre-omicron asymptomatic SARS-CoV-2 infection in unvaccinated participants in a prospective population-based study in the United States (191 asymptomatic vs. 945 symptomatic COVID-19 cases). Moreover, we found no such association in the international COVID Human Genetic Effort cohort (206 asymptomatic vs. 574 mild or moderate COVID-19 cases and 1,625 severe or critical COVID-19 cases). Finally, in the Human Challenge Characterisation study, the three HLA-B∗15:01 individuals infected with SARS-CoV-2 developed symptoms. As with other acute primary infections studied, no classical HLA alleles favoring an asymptomatic course of SARS-CoV-2 infection were identified., The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1 TR001866), the Yale Center for Mendelian Genomics and the GSP Coordinating Center funded by the National Human Genome Research Institute (NHGRI) (UM1HG006504 and U24HG008956), the Yale High Performance Computing Center (S10OD018521), the Fisher Center for Alzheimer's Research Foundation, the JPB Foundation, the Meyer Foundation, the French National Research Agency (ANR) under the “Investments for the Future” program (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBEID), the French Foundation for Medical Research (FRM) (Equation 201903007798), the ANRS-COV05, ANR GENVIR (ANR-20-CE93-003), and ANR AI2D (ANR-22-CE15-0046) projects, the ANR-RHU program (ANR-21-RHUS-08), the European Union’s Horizon 2020 research and innovation program under grant agreement No. 824110 (EASI-genomics), the HORIZON-HLTH-2021-DISEASE-04 program under grant agreement 101057100 (UNDINE), the Square Foundation, Grandir - Fonds de solidarité pour l’enfance, Fondation du Souffle, the SCOR Corporate Foundation for Science, William E. Ford, General Atlantic’s Chairman and Chief Executive Officer, Gabriel Caillaux, General Atlantic’s Co-President, Managing Director and Head of business in EMEA, and the General Atlantic Foundation, the Battersea & Bowery Advisory Group, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris Cité. A.N.S. is supported by European Union’s Horizon Health research and innovation program under grant agreement No. 101057100, project UNDINE. S.G.T. is supported by an Investigator Grant awarded by the National Health and Medical Research Council of Australia, and a University of New South Wales Sydney COVID Rapid Response Initiative grant. The study was supported by the ORCHESTRA project, which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 10101616. The French COVID Cohort study group was sponsored by Inserm and supported by the REACTing consortium and by a grant from the French Ministry of Health (Grant PHRC 20-0424). The Cov-Contact Cohort was supported by the REACTing consortium, the French Ministry of Health, European Commission (Grant RECOVER WP 6). The COVIDeF study group was supported by the French Ministry of Health and Fondation AP-HP Programme Hospitalier de Recherche Clinique (PHRC COVID-19-20-0048). Y.Z. is supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, NIH. This project has received funding from the Regione Lazio (Research Group Projects 2020) No. A0375-2020-36663, GecoBiomark, the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation program (grant agreement no. 948959), the Swiss National Science Foundation (grant # 310030L_197721 to J.F.), and ERN-RITA. The Canarian Sequencing Hub is funded by Instituto de Salud Carlos III (COV20_01333, COV20_01334, and PI20/00876) and Spanish Ministry of Science and Innovation (RTC-2017-6471-1; AEI/FEDER, UE), co-financed by the European Regional Development Funds, “A way of making Europe” from the European Union, Cabildo Insular de Tenerife (CGIEU0000219140 and “Apuestas científicas del ITER para colaborar en la lucha contra la COVID-19”). This work was funded, at least in part, by grants AJF202019 and AJF20259 from Al Jalila Foundation, Dubai, United Arab Emirates. Sample processing at IrsiCaixa was possible thanks to the crowdfunding initiative YoMeCorono. We thank I. Erkizia, E. Grau, M. Massanella, and J. Guitart from the IrsiCaixa and Hospital Germans Trias i Pujol (Badalona, Spain) for sample collection, handling, and processing.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Opportunities for CAR-T Cell Immunotherapy in HIV Cure

  • Campos-Gonzalez, Gerard|||0000-0002-5442-4963
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
  • Velasco-Hernández, Talia|||0000-0003-2183-7443
  • Salgado, Maria|||0000-0003-1551-7216
Chimeric antigen receptor (CAR) technology is having a huge impact in the blood malignancy field and is becoming a well-established therapy for many types of leukaemia. In recent decades, efforts have been made to demonstrate that CAR-T cells have potential as a therapy to achieve a sterilizing cure for human immunodeficiency virus (HIV) infection. However, translation of this technology to the HIV scenario has not been easy, as many challenges have appeared along the way that hinder the consolidation of CAR-T cells as a putative therapy. Here, we review the origin and development of CAR-T cells, describe the advantages of CAR-T cell therapy in comparison with other therapies, and describe the major obstacles currently faced regarding application of this technology in the HIV field, specifically, viral escape, CAR-T cell infectivity, and accessibility to hidden reservoirs. Nonetheless, promising results in successfully tackling some of these issues that have been obtained in clinical trials suggest a bright future for CAR-T cells as a consolidated therapy.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Preclinical development of humanized monoclonal antibodies against CD169 as a broad antiviral therapeutic strategy

  • Resa-Infante, Patricia|||0000-0002-1727-592X
  • Erkizia, Itziar|||0000-0003-1244-8972
  • Muñiz-Trabudua, Xabier|||0000-0002-1142-4381
  • Linty, Federica
  • Bentlage, Arthur E.H.
  • Perez-Zsolt, Daniel|||0000-0003-4192-7622
  • Muñoz-Basagoiti, Jordana|||0000-0002-0384-5928
  • Raïch-Regué, Dàlia|||0000-0001-7656-5700
  • Izquierdo Useros, Nuria|||0000-0002-1039-1821
  • Rispens, Theo
  • Vidarsson, Gestur
  • Martínez Picado, Francisco Javier|||0000-0002-4916-2129
New therapies to treat or prevent viral infections are essential, as recently observed during the COVID-19 pandemic. Here, we propose a therapeutic strategy based on monoclonal antibodies that block the specific interaction between the host receptor Siglec-1/CD169 and gangliosides embedded in the viral envelope. Antibodies are an excellent option for treating infectious diseases based on their high specificity, strong targeting affinity, and relatively low toxicity. Through a process of humanization, we optimized monoclonal antibodies to eliminate sequence liabilities and performed biophysical characterization. We demonstrated that they maintain their ability to block viral entry into myeloid cells. These molecular improvements during the discovery stage are key if we are to maximize efforts to develop new therapeutic strategies. Humanized monoclonal antibodies targeting CD169 provide new opportunities in the treatment of infections caused by ganglioside-containing enveloped viruses, which pose a constant threat to human health. In contrast with current neutralizing antibodies that bind antigens on the infectious particle, our antibodies can prevent several types of enveloped viruses interacting with host cells because they target the host CD169 protein, thus becoming a potential pan-antiviral therapy.